Recent Updates
Recently added Catalysts
TLPH Neutral Sentiment Score: 60/100

Talphera to Host Second Quarter Financial Results and Corporate Update Call and Webcast on Thursday, August 14, 2025

Key Takeaway: Talphera, Inc. will release its second quarter financial results on August 14, 2025, after market close. Following the release, the company will conduct a live webcast and conference call to discuss the results and provide business updates. The event can be accessed via the company's website, and a replay will be available for 90 days. Talphera focuses on innovative therapies with its lead product candidate, Niyad™, currently under investigation as an anticoagulant and designated as a Breakthrough Device by the FDA.

Market Sentiment Analysis

POSITIVE FACTORS

  • Talphera is set to announce its second quarter financial results, indicating potential updates on performance.
  • The company has received Breakthrough Device Designation from the FDA for its lead product candidate, Niyad™, showing promise in its development.

Full Press Release Details

SAN MATEO, Calif., Aug. 7, 2025 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release second quarter 2025 financial results after market close on Thursday, August 14, 2025, then host a live webcast and conference call at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss the results and provide an update on the Company's business.
The webcast can be accessed here or by visiting the Investors section of the Company's website at www.talphera.com and clicking on the webcast link posted within Investors/News & Events/Upcoming Events section. The webcast will include a slide presentation and a replay will be available on the Talphera website for 90 days following the event.
Conference Call Information
Investors who wish to participate in the conference call may do so by dialing 1-800-836-8184 for North American callers, or 1-646-357-8785 (toll applies) for international callers outside of Canada. The conference ID is 32530.
About Talphera, Inc.
Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. Talphera's lead product candidate, Niyad™ is a lyophilized formulation of nafamostat and is currently being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit, and has received Breakthrough Device Designation status from the U.S. Food and Drug Administration (FDA).
This release is intended for investors only. For additional information about Talphera, please visit www.talphera.com.
SOURCE Talphera, Inc.

21 %

more press release views with

Frequently Asked Questions

When will Talphera release its Q2 2025 financial results?

Talphera will release its Q2 2025 financial results on August 14, 2025.

How can I access the Talphera webcast?

The Talphera webcast can be accessed via their website under the Investors section.

What is Talphera's lead product candidate?

Talphera's lead product candidate is Niyad™, a formulation of nafamostat.

What designation has Niyad™ received from the FDA?

Niyad™ has received Breakthrough Device Designation status from the FDA.

How can investors join the Talphera conference call?

Investors can dial 1-800-836-8184 for North America or 1-646-357-8785 internationally.

Last updated: Aug 7, 2025